Christoph Henkenberens1, Christoph A VON Klot2, Tobias L Ross3, Frank M Bengel3, Hans-Jürgen Wester4, Hüper Katja5, Hans Christiansen6, Thorsten Derlin3. 1. Department of Radiation Oncology, Hannover Medical School, Hannover, Germany henkenberens.christoph@mh-hannover.de. 2. Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany. 3. Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany. 4. Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany. 5. Department of Radiology, Hannover Medical School, Hannover, Germany. 6. Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
Abstract
AIM: To evaluate 68Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0.52-8.92) ng/ml to a nadir of 1.37 (range=0.11-8.00) ng/ml (p=0.001) following radiotherapy. Except for one patient (4.4%), PSA level decreased in 22 patients (95.6%). The biochemical failure-free survival and time to initiation of systemic therapy at the median follow-up were 95.6% and 100%, respectively. Three patients (12.9%) presented with recurrent disease outside the initial radiation field. No grade III acute toxicities or late grade II toxicities were observed. CONCLUSION: 68Ga-PSMA ligand PET/CT-based radiotherapy is a promising local treatment option for isolated lymph node metastases of prostate cancer. Copyright
AIM: To evaluate 68Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0.52-8.92) ng/ml to a nadir of 1.37 (range=0.11-8.00) ng/ml (p=0.001) following radiotherapy. Except for one patient (4.4%), PSA level decreased in 22 patients (95.6%). The biochemical failure-free survival and time to initiation of systemic therapy at the median follow-up were 95.6% and 100%, respectively. Three patients (12.9%) presented with recurrent disease outside the initial radiation field. No grade III acute toxicities or late grade II toxicities were observed. CONCLUSION: 68Ga-PSMA ligand PET/CT-based radiotherapy is a promising local treatment option for isolated lymph node metastases of prostate cancer. Copyright
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469
Authors: Julian Müller; Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Sarah Kedzia; Daniel Eberli; Matthias Guckenberger; Stephanie G C Kroeze; Tullio Sulser; Daniel M Schmid; Aurelius Omlin; Alexander Müller; Thomas Zilli; Hubert John; Helmut Kranzbuehler; Philipp A Kaufmann; Gustav K von Schulthess; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-28 Impact factor: 9.236
Authors: Nina-Sophie Schmidt-Hegemann; Christian Stief; Tak-Hyun Kim; Chukwuka Eze; Simon Kirste; Iosif Strouthos; Minglun Li; Wolfgang Schultze-Seemann; Harun Ilhan; Wolfgang Peter Fendler; Peter Bartenstein; Anca-Ligia Grosu; Ute Ganswindt; Claus Belka; Philipp T Meyer; Constantinos Zamboglou Journal: J Nucl Med Date: 2018-07-12 Impact factor: 10.057
Authors: Sebastian Zschaeck; Fabian Lohaus; Marcus Beck; Gregor Habl; Stephanie Kroeze; Constantinos Zamboglou; Stefan Alexander Koerber; Jürgen Debus; Tobias Hölscher; Peter Wust; Ute Ganswindt; Alexander D J Baur; Klaus Zöphel; Nikola Cihoric; Matthias Guckenberger; Stephanie E Combs; Anca Ligia Grosu; Pirus Ghadjar; Claus Belka Journal: Radiat Oncol Date: 2018-05-11 Impact factor: 3.481
Authors: Marco M E Vogel; Stephanie G C Kroeze; Christoph Henkenberens; Nina-Sophie Schmidt-Hegemann; Simon Kirste; Jessica Becker; Irene A Burger; Thorsten Derlin; Peter Bartenstein; Michael Mix; Christian la Fougère; Matthias Eiber; Hans Christiansen; Claus Belka; Anca L Grosu; Arndt-Christian Müller; Matthias Guckenberger; Stephanie E Combs Journal: Eur J Nucl Med Mol Imaging Date: 2020-03-16 Impact factor: 9.236